Are dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.
Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.
Our latest HIV market snapshot, reveals that 2 in 3 patients are currently treated with an STR (Single-tablet regimen) and more than half are treated with InSTIs (Integrase strand transfer inhibitors). Therapy Watch HIV patient data is collected bi-monthly from a panel of 225 physicians across the main 5 EU markets.
How buyer insights supported the development of an effective market strategy
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.
Investigating factors affecting time to initiation of hepatitis treatment
Following the Viral Hepatitis Congress 2014 in Germany where Darren Kottler presented a poster presentation, he shares some of the factors affecting time from diagnosis to initiation of therapy in hepatitis patients.
By analysing the factors that lead to a patient to be treated for hepatitis, Therapy Watch data can illustrate the key elements of the patient’s condition that lead to one patient being treated sooner than another.
Eliminating Stigma: A consideration of the role the pharmaceutical industry can play
My recent article in Medical Marketing & Media explored the importance of vaccine perceptions in a self-pay market and touched upon the issue of stigma, with the recognition that some diseases or conditions are so taboo in society that for physicians to merely suggest the idea of vaccination to their patients is to risk casting aspersions on their lifestyle. In this blog , I aim to take a more in-depth look at what stigma means in the context of healthcare and consider the opportunities and challenges for pharma.
As specialists in healthcare, stigma is something we frequently encounter across many of the disease areas in which we work. This is most evident when we are conducting research directly with patients and particularly in the emerging markets, which is my team’s focus. From sexually transmitted diseases to mental illness, shame may be associated with their condition and is a devastating reality for many of the patients we seek to understand.